Current Hypertension Reports

, Volume 9, Issue 4, pp 264–268

Prehypertension: Demographics, pathophysiology, and treatment



The term prehypertension, which first appeared in the Seventh Report of the Joint National Committee (JNC 7) in 2003, has sparked controversy in the field of hypertension. Systolic blood pressure (BP) rises with age in industrialized societies, but an individual’s rate of rise of systolic BP and the age at which BP crosses the arbitrary threshold of hypertension depends on prior BP levels (hence “prehypertension”). Obesity, another major factor in prehypertension, activates neurohumoral systems (renin-angiotensin and sympathetic nervous) and contributes to age-related BP increases. The JNC 7 recommendation for prehypertension management with optimal weight control (largely through diet and exercise) remains the mainstay, especially in the elderly. The Trial of Prevention of Hypertension demonstrated that angiotensin receptor blockade (ARB) retards age-related BP increases in prehypertensive patients. Associated elevated risk conditions (prediabetes, hypercholesterolemia, microalbuminuria) may justify early use of ARB therapy (in men and in women without childbearing potential) if weight control fails.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: JNC 7 express. JAMA 2003, 289:2560–2572.PubMedCrossRefGoogle Scholar
  2. 2.
    Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population: results from the third national health and nutrition examination survey, 1988–1991. Hypertension 1995, 25:305–313.PubMedGoogle Scholar
  3. 3.
    Franklin SS, Gustin WT, Wong ND, et al.: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997, 96:308–315.PubMedGoogle Scholar
  4. 4.
    Vasan RS, Beiser A, Seshadri S, et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002, 287:1003–1010.PubMedCrossRefGoogle Scholar
  5. 5.
    Hollenberg NK, Martinez G, McCullough M, et al.: Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension 1997, 29:171–176.PubMedGoogle Scholar
  6. 6.
    Izzo JL Jr, Levy D, Black HR: Clinical advisory statement: importance of systolic blood pressure in older Americans. Hypertension 2000, 35:1021–1024.PubMedGoogle Scholar
  7. 7.
    Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.PubMedCrossRefGoogle Scholar
  8. 8.
    Franklin SS, Jacobs MJ, Wong ND, et al.: Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001, 37:869–874.PubMedGoogle Scholar
  9. 9.
    Neaton JD, Wentworth D, Group MR: Serumcholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med 1992, 152:56–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Benetos A, Zureik M, Morcet J, et al.: A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000, 35:673–680.PubMedCrossRefGoogle Scholar
  11. 11.
    Giles TD, Berk BC, Black HR, et al.: Expanding the definition and classification of hypertension. J Clin Hypertens 2005, 7:505–512.CrossRefGoogle Scholar
  12. 12.
    Julius S, Nesbitt SD, Egan BM, et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354:1685–1697.PubMedCrossRefGoogle Scholar
  13. 13.
    Julius S, Krause L, Schork NJ, et al.: Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens 1991, 9:77–84.PubMedGoogle Scholar
  14. 14.
    Drukteinis JS, Roman MJ, Fabsitz RR, et al.: Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation 2007, 115:221–227.PubMedCrossRefGoogle Scholar
  15. 15.
    Sung BH, Wilson MF, Izzo JL Jr, et al.: Moderately obese, insulin-resistant women exhibit abnormal vascular reactivity to stress. Hypertension 1997, 30:848–853.PubMedGoogle Scholar
  16. 16.
    Sung BH, Izzo JL Jr, Wilson MF: Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997, 10: 592–599.PubMedCrossRefGoogle Scholar
  17. 17.
    Messerli FH, Sundgaard-Riise K, Ventura HO, et al.: Essential hypertension in the elderly: haemodynamics, intravascular volume, plasm a renin activity, and circulating catecholamine levels. Lancet 1983, 2:983–986.PubMedCrossRefGoogle Scholar
  18. 18.
    Izzo JL Jr, Smith RJ, Larrabee PS, Kallay MC: Plasma norepinephrine and age as determinants of systemic hemodynamics in men with established essential hypertension. Hypertension 1987, 9:415–419.PubMedGoogle Scholar
  19. 19.
    Mitchell GF, Lacourciere Y, Ouellet JP, et al.: Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation 2003, 108:1592–1598.PubMedCrossRefGoogle Scholar
  20. 20.
    Svetkey LP, Erlinger TP, Vollmer WM, et al.: Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. J Hum Hypertens 2005, 19:21–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Straznicky NE, Lambert EA, Lambert GW, et al.: Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 2005, 90:5998–6005.PubMedCrossRefGoogle Scholar
  22. 22.
    Haller H, Viberti GC, Mimran A, et al.: Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study. J Hypertens 2006, 24:403–408.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Erie County Medical CenterState University of New York at BuffaloBuffaloUSA

Personalised recommendations